“United Dream, Shared Success” 2013 Chinese Clinical Oncology Advances Awards Announced

From China Medical Tribune

In January 2014, "2013 Chinese Clinical Oncology Advances Awards " organized by China Medical Tribune (CMT) and the Chinese Society of Clinical Oncology (CSCO) has finalized the top researches from China (a number of studies have tied votes).

The achievements of Chinese clinical and basic oncology researches have attracted global attention in the past 2013.
In this election, 46 Chinese oncologists from 23 hospitals in China have been invited to be core election reviewers. In addition, Professor Peter Paul Yu, president-elected of American Society of Clinical Oncology (ASCO), Professor David Kerr, pre-president of European Society for Medical oncology (ESMO), Professor Masahiko Nishiyama, president of Japan Society of Clinical Oncology (JSCO), scholars from the United States Chinese Anti-Cancer Association (USCACA), Professor Li Yan and Professor Weijin Sun (University of Pittsburgh Medical Center)  also have been invited to be special reviewers for this election.

“The candidate researches for the awards are studies of high quality – all were published on predigous sentific journals, with 19 of them published on Lancet Oncology or Journal of Clinical Oncology.  The fingdings may play important roles in oncology field.  Chinese oncolgiests have a ‘bumper crop’ in 2013 ……”,Professor Yilong Wu, president of CSCO said.

“Chinese clinical oncologists have made great efforts and completed a series clinical oncology trials with the potential of practice-changing in the past year……”, “we expect that more studies presented on academic conferences or studies published on authoritative Chinese journals would be included to the election in the coming year. We hope that the election could be a way to promote the progress of Chinese oncology……”, Professor Shukui Qin ,immediate past-president of CSCO .

“Chinese oncologists have contributed a lot to the progress in clinical oncology.  In China, various large-scale clinical trials in a variety of cancers have been performed and provided very prominent results”, “A number of clinical studies have clearly demonstrated ethnic diversity in drug response and toxicity. This studies give hope for further progress in clinical oncology and improving patient outcomes in Asia.”, Professor Nishiyama said.

In recent years, there are increasing number of valuable clinical oncology studies designed and carried out by Chinese researchers published on the leading journals in the field.  Chinese oncologists are prepared and readily to devote more efforts in clinical oncology study and to cooperate with peer oncologists around world.


Elected researches listed by publishing date:

1. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Corresponding Author: Haiquan Chen
Affiliation: Fudan University Shanghai Cancer Center, Shanghai, China.
J Clin Oncol.  2012 Dec 10;30(35):4352-9. doi: 10.1200/JCO.2012.44.1477.

2. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.
Corresponding Author: Minshan Chen
Affiliation: Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China
J Clin Oncol.  2013 Feb 1;31(4):426-32. doi: 10.1200/JCO.2012.42.9936.

3. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Corresponding Author: Zhiyuan Zhang
Affiliation: Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
J Clin Oncol. 2013 Feb 20;31(6):744-51. doi: 10.1200/JCO.2012.43.8820.

4.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.
Corresponding Author: Feng Shen
Affiliation: Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
J Clin Oncol. 2013 Mar 20;31(9):1188-95. doi: 10.1200/JCO.2012.41.5984.

5. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Corresponding Author:  Jianmin Xu
Affiliation: Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
J Clin Oncol. 2013 Jun 1;31(16):1931-8. doi: 10.1200/JCO.2012.44.8308.

6. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Corresponding Author:  Zhongzhen Guan
Affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.
J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241

7. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
Corresponding Author:  Jie Jin
Affiliation: First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
Lancet Oncol. 2013 Jun;14(7):599-608. doi: 10.1016/S1470-2045(13)70152-9

8. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Corresponding Author: Yilong Wu,Tony Mok
Affiliation: Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7.

9. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Corresponding Author: Yi-Hsiang Huang
Affiliation: Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan, China.
J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938.

10. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Corresponding Author: Yan Sun
Affiliation: Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3

11. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Corresponding Author: Jin Li
Affiliation: Shanghai Cancer Center and Shanghai Medical College, Fudan University,China.
J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585.

12.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Corresponding Author: Shukui Qin
Affiliation: People's Liberation Army Cancer Centre, Bayi Hospital, Nanjing, China.
J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643.

13. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Corresponding Author: Xiaojun Huang
Affiliation: Peking University People's Hospital, Beijing, China.
J Clin Oncol. 2013 Nov 20;31(33):4215-21. doi: 10.1200/JCO.2013.48.8312.

14. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Corresponding Author: Junhang Luo
Affiliation: First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1.